DCI Partners

Apeximmune Therapeutics is pioneering a new generation of therapeutic antibodies and biologics that harness the power of the immune system to deliver curative treatments for cancer and autoimmune disease.

Luxna Biotech Co., Ltd. is a Japanese company focused on the development of nucleic acid drugs, utilizing advanced technology to enhance the practical application of these therapies. Founded in 2017 and based in Suita, Japan, the company provides drug discovery support through artificial nucleic acid technology. Luxna Biotech aims to contribute to medical treatment, addressing the needs of patients with various health conditions.

aceRNA Technologies is a biotechnology startup focused on developing innovative genetic therapies utilizing RNA switch technology. The company specializes in regenerative medicine, aiming to discover novel functions of microRNAs (miRNAs) that can regulate gene expression. By harnessing this technology, aceRNA Technologies seeks to facilitate the removal of undifferentiated and potentially cancerous cells, thereby enhancing drug discovery and therapeutic applications. Through its patient-centric approach, the company strives to advance the field of genetic therapies and improve treatment outcomes in various medical conditions.

LUCA Science Inc. is a biotechnology company based in Japan that focuses on developing innovative mitochondrial therapies aimed at restoring bioenergetics in damaged tissues and organs. Utilizing its patented iMIT technology, the company creates a platform that delivers functional mitochondria to affected areas, potentially boosting cellular energy and normalizing physiological functions. This approach has the potential to address various unmet medical needs by employing mitochondria as biopharmaceutical agents, marking a significant advancement in the treatment of conditions related to impaired cellular energy production. LUCA Science is dedicated to improving disease management by enhancing mitochondrial activity and stability.

K Pharma is engaged in the research, development, manufacturing, and marketing of pharmaceuticals, with a particular focus on neuro regenerative medicine. The company utilizes induced pluripotent stem (iPS) cell technology to create innovative treatments for neurological conditions, including cerebral infarction and spinal cord injury. By combining advanced drug discovery methods with a commitment to developing medical products, K Pharma aims to address significant unmet needs in the field of regenerative medicine.

Elixiron Immunotherapeutics is focused on developing innovative therapeutics for cancer, neurological diseases, and inflammatory disorders. The company specializes in immuno-therapeutics aimed at addressing conditions such as neurodegenerative diseases and Hepatitis B, as well as various cancer types. Its drug candidates are designed to target specific immuno-suppressive pathways, including graft-versus-host disease and macrophage activation syndrome. By doing so, Elixiron seeks to empower patients to effectively utilize their immune systems in the fight against these serious health challenges.

Renascience is a research and development firm focused on creating innovative medical solutions to address various health issues. The company engages in the development of pharmaceuticals and medical devices, employing diverse methodologies including artificial intelligence to enhance its offerings. By integrating these advanced technologies, Renascience aims to solve complex medical challenges and improve patient outcomes.

Junten Bio is focused on the research and development of cell-based therapies utilizing regenerative medicine technology. The company aims to enhance medical treatment options by investigating the mechanisms of immune rejection in vivo. Through its work, Junten Bio develops innovative cellular solutions that address the side effects associated with the use of immunosuppressive agents following organ transplantation. By improving patient outcomes and quality of life, the company seeks to reduce overall medical expenses related to transplant procedures.

StemRIM is a biotechnology company based in Ibaraki, Japan, founded in 2006. The company specializes in the development of regeneration-guided medicines aimed at treating challenging diseases such as epidermolysis bullosa, cerebral infarction, and myocardial infarction. StemRIM's innovative approach involves mobilizing the body's own stem cells to target injured or diseased tissues without the need for extraction. Their product portfolio includes PJ1 regeneration induction medicine using HMGB1 peptides, PJ2 and PJ3 regeneration-inducing drugs and proteins, as well as the PJ4 therapeutic autologous cell collection device and PJ5 stem cell gene therapy technology. Through its research and development efforts, StemRIM seeks to advance the field of regenerative medicine and provide effective treatment options for patients with intractable conditions.

Noile-Immune Biotech Inc, founded in 2015 and based in Minato-ku, Japan, focuses on the research and development of innovative cancer immunotherapies, particularly utilizing CAR-T cell therapy. The company aims to advance treatment options for cancer patients by harnessing the potential of this cutting-edge technology. As a key player in the field, Noile-Immune Biotech is committed to becoming a leader in the next generation of cancer immunotherapy solutions.

Renascience is a research and development firm focused on creating innovative medical solutions to address various health issues. The company engages in the development of pharmaceuticals and medical devices, employing diverse methodologies including artificial intelligence to enhance its offerings. By integrating these advanced technologies, Renascience aims to solve complex medical challenges and improve patient outcomes.

Aprinoia Therapeutics Inc. is a clinical-stage biotechnology company focused on the research, development, and manufacturing of innovative diagnostic tools for the detection of neurological diseases. Established in 2015 and headquartered in Taipei, Taiwan, with additional locations in China and Japan, the company specializes in advanced imaging techniques, notably the 18F-PM-PBB3 tau positron-emission tomography (PET) imaging tracer. This tracer aids in diagnosing tauopathies and supports the development of therapeutic programs for conditions such as Alzheimer's disease, Parkinson's disease, and dementia. Additionally, Aprinoia manufactures an alpha-synuclein PET imaging tracer. The company's mission is to enhance brain health and improve clinical outcomes for patients suffering from various neurodegenerative diseases by leveraging precision medicine to target harmful protein aggregates involved in these conditions.

BONAC Corporation focuses on the research, development, manufacturing, and commercialization of nucleic acid pharmaceutical products, utilizing advanced nucleic acid platform technology. Established in 2010 and headquartered in Kurume, Japan, with an office in Tokyo, the company specializes in the production and sale of nucleic acid ingredients. BONAC offers a comprehensive suite of services that includes drug substance manufacturing and support for drug development, aiming to facilitate access to innovative drug substances for pharmaceutical and cosmetic manufacturers. Through its efforts, BONAC addresses unmet medical needs by advancing RNA technology and developing effective nucleic acid medicines.